
EVOK
Evoke Pharma Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.500
Open
4.350
VWAP
--
Vol
41.74K
Mkt Cap
6.51M
Low
4.290
Amount
--
EV/EBITDA(TTM)
--
Total Shares
8.60M
EV
-1.12M
EV/OCF(TTM)
--
P/S(TTM)
0.83
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
4.66M
+40.76%
--
--
4.33M
+62.99%
--
--
3.80M
+48.78%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Evoke Pharma, Inc. (EVOK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 62.08%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Up

+62.08%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Evoke Pharma Inc (EVOK.O) is -11.51, compared to its 5-year average forward P/E of -5.26. For a more detailed relative valuation and DCF analysis to assess Evoke Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.26
Current PE
-11.51
Overvalued PE
-0.37
Undervalued PE
-10.16
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.38
Undervalued EV/EBITDA
-0.22
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
6.51
Current PS
0.49
Overvalued PS
18.27
Undervalued PS
-5.25
Financials
Annual
Quarterly
FY2025Q1
YoY :
+77.48%
3.08M
Total Revenue
FY2025Q1
YoY :
-13.29%
-1.30M
Operating Profit
FY2025Q1
YoY :
-17.32%
-1.31M
Net Income after Tax
FY2025Q1
YoY :
-75.60%
-0.51
EPS - Diluted
FY2025Q1
YoY :
+4.20%
98.65
Gross Profit Margin - %
FY2025Q1
YoY :
-53.41%
-42.41
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
180.0
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
180.0
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
EVOK News & Events
Events Timeline
2025-07-09 (ET)
2025-07-09
08:31:28
Evoke Pharma receives notice of allowance for use of GIMOTI from USPTO

2025-07-09
08:26:37
Evoke Pharma receives notice of allowance from USPTO for Gimoti patent

2025-04-28 (ET)
2025-04-28
08:40:33
Evoke Pharma to present new data comparing TD receiving OCMP treatment

Sign Up For More Events
Sign Up For More Events
News
7.5
07-17GlobenewswireWilliam Hill and Inspired Extend Long-Term Partnership with Enhanced Virtual Sports Experience Through Expanded Retail Rollout
4.5
07-09BenzingaCrude Oil Moves Higher; RxSight Shares Plunge
3.5
07-09BenzingaEvoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?
Sign Up For More News
People Also Watch

SOAR
Volato Group Inc
1.710
USD
-5.00%

XHG
XChange TEC.INC
1.310
USD
-1.50%

ONFO
Onfolio Holdings Inc
1.240
USD
-5.34%

UBXG
U-BX Technology Ltd
3.106
USD
+0.84%

PLRZ
Polyrizon Ltd
1.450
USD
-5.84%

CREG
Smart Powerr Corp
1.900
USD
-9.52%

BLBX
Blackboxstocks Inc
7.620
USD
+2.28%

GRI
GRI Bio Inc
2.140
USD
+7.54%

CMND
Clearmind Medicine Inc
1.020
USD
-0.97%

IMG
CIMG Inc
0.256
USD
-0.78%
FAQ

What is Evoke Pharma Inc (EVOK) stock price today?
The current price of EVOK is 4.36 USD — it has decreased -1.58 % in the last trading day.

What is Evoke Pharma Inc (EVOK)'s business?

What is the price predicton of EVOK Stock?

What is Evoke Pharma Inc (EVOK)'s revenue for the last quarter?

What is Evoke Pharma Inc (EVOK)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Evoke Pharma Inc (EVOK)'s fundamentals?

How many employees does Evoke Pharma Inc (EVOK). have?
